One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Citius Pharmaceuticals logo
Citius Pharmaceuticals CTXR
$ 0.51 4.08%
report update icon

Quarterly report 2026-Q2
added 05-15-2026

Citius Pharmaceuticals Balance Sheet 2025-2010 | CTXR

Brief overview of Citius Pharmaceuticals's financial position

Balance sheet changes are traced across five available annual reports between 2021 and 2025.

Assets declined from $142.4 million to $130.9 million, or -8.1%. The contraction calls for context such as disposals, restructuring or weaker operations.

Liability growth of +453.7% exceeded asset growth of -8.1%, increasing reliance on outside funding.

Internal capital represents 51.6% of the balance sheet, previously 92.8%. This is a strong capital position.

The balance sheet holds more cash than interest-bearing debt; net debt is -$3.4 million, indicating minimal leverage.

The cash share moved from 49.2% to 3.2%. A higher figure generally provides more room in an adverse scenario.

The accumulated result is -$238.8 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.

What the balance sheet shows

Taken together, the figures indicate acceptable resilience for Citius Pharmaceuticals. The next assessment depends on debt and equity trends.

Annual Balance Sheet Citius Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Net Debt

-3.44 M -2.99 M -26 M -41 M -69.2 M -13.5 M -7.72 M -9.01 M -3.03 M 379 K -676 K -952 K 3.21 K 16.9 K 18.3 K -

Long Term Debt

725 K 21.3 K 263 K 481 K 678 K 165 K - - - - - - - - - -

Long Term Debt Current

88.3 K 242 K 218 K 197 K 177 K 159 K - - - - - - - - - -

Total Non Current Liabilities

- - - - - 6.01 M - - - - - - - - - -

Total Current Liabilities

44.9 M 35.8 M 5.78 M 4.53 M 3.98 M 4.1 M 4.61 M 3.18 M 2.47 M 5.18 M 1.38 M 2.3 M 14.7 K 46 K 24.1 K -

Total Liabilities

53.4 M 42.5 M 12.2 M 10.6 M 9.65 M 10.1 M 4.61 M 3.18 M 2.47 M 5.18 M 1.38 M 2.3 M 14.7 K 46 K 24.1 K -

Retained Earnings

-239 M -201 M -162 M -130 M -96 M -70.6 M -55.8 M -40.3 M -27.7 M -17.3 M -9.04 M -6.14 M -95.2 K -63.8 K -41.8 K -

Total Assets

131 M 117 M 104 M 114 M 142 M 43.8 M 29 M 31.1 M 24.4 M 22 M 742 K 1.56 M - 135 212 2.5 K

Cash and Cash Equivalents

4.25 M 3.25 M 26.5 M 41.7 M 70.1 M 13.9 M 7.89 M 9.18 M 3.2 M 294 K 676 K 1.55 M 54.4 K 41.7 K 212 -

Book Value

77.5 M 74.1 M 91.4 M 103 M 133 M 33.7 M 24.4 M 27.9 M 21.9 M 16.8 M -635 K -742 K -14.7 K -45.8 K -23.8 K 2.5 K

Total Shareholders Equity

67.6 M 70.1 M 90.8 M 103 M 132 M 33.7 M 24.4 M 27.9 M 21.9 M 16.8 M -635 K -742 K -2.9 M -1.61 M -23.8 K 2.5 K

All numbers in USD currency

Quarterly Balance Sheet Citius Pharmaceuticals

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

637 K 682 K 682 K 725 K 767 K 787 K - 21.3 K 84.4 K 145 K 205 K 263 K 320 K 375 K 429 K 481 K 533 K 582 K 631 K 678 K 725 K 678 K 813 K 855 K 855 K 855 K 976 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

63.5 M 46.9 M 46.9 M 53.4 M 60.1 M 57.9 M 51.8 M 42.5 M 10.8 M 10.7 M 12.1 M 12.2 M 12.1 M 12.4 M 10.7 M 10.6 M 9.98 M 9.59 M 13 M 9.65 M 9.31 M 9.65 M 9.51 M 10.1 M 10.1 M 10.1 M 4.61 M 9.59 M 4.61 M 4.61 M - - - - - - - - - - - - - - - - - 2.3 M - - 3.01 M - - - - - - - - - - -

Retained Earnings

-268 M -247 M -247 M -239 M -231 M -222 M -211 M -201 M -191 M -180 M -171 M -162 M -152 M -144 M -133 M -130 M -122 M -113 M -105 M -96 M -91.1 M -96 M -81.1 M -70.6 M -70.6 M -70.6 M -60.1 M -53 M -55.8 M -55.8 M -44.1 M -40.3 M -40.3 M -40.3 M -31 M -27.7 M -27.7 M -27.7 M -19.5 M -17.3 M -17.3 M -17.3 M -10.3 M -9.04 M -9.04 M -9.04 M -6.96 M -6.14 M -6.14 M -6.14 M -5.4 M - - - - - - - - - - -

Total Assets

133 M 140 M 140 M 131 M 128 M 121 M 121 M 117 M 97.1 M 90.7 M 97.4 M 104 M 110 M 104 M 112 M 114 M 120 M 128 M 138 M 142 M 147 M 142 M 35.3 M 43.8 M 43.8 M 43.8 M 25 M 36.7 M 29 M 29 M 28.1 M 31.1 M 31.1 M 31.1 M 28.5 M 24.4 M 24.4 M 24.4 M 21.5 M 22 M 22 M 22 M 347 K 742 K 742 K 742 K 823 K 1.56 M 1.56 M 1.56 M 108 K - - 5.95 K 99 135 135 135 216 212 212 212

Cash and Cash Equivalents

4.59 M 7.72 M 7.72 M 4.25 M 6.09 M 26.4 K 1.1 M 3.25 M 17.9 M 12.6 M 20.3 M 26.5 M 33.3 M 29.1 M 36.9 M 41.7 M 48 M 55.8 M 65.4 M 70.1 M 116 M 70.1 M 4.3 M 13.9 M 13.9 M 4.3 M 2.78 M 7.89 M 7.89 M 2.78 M 7.04 M 9.18 M 9.18 M 7.04 M 7.37 M 3.2 M 3.2 M 7.37 M 46.8 K 294 K 294 K 46.8 K 281 K 676 K 676 K 281 K 817 K 1.55 M 1.55 M 817 K 54.4 K 1.27 K - - 41.7 K 135 135 99 61.5 K 212 212 216

Book Value

69.1 M 93.5 M 93.5 M 77.5 M 67.6 M 63.6 M 68.9 M 74.1 M 86.3 M 80 M 85.3 M 91.4 M 98.3 M 91.8 M 101 M 103 M 110 M 118 M 125 M 133 M 137 M 133 M 25.8 M 33.7 M 33.7 M 33.7 M 20.4 M 27.2 M 24.4 M 24.4 M 28.1 M 31.1 M 31.1 M 31.1 M 28.5 M 24.4 M 24.4 M 24.4 M 21.5 M 22 M 22 M 22 M 347 K 742 K 742 K 742 K 823 K -742 K 1.56 M 1.56 M -2.9 M - - 5.95 K 99 135 135 135 216 212 212 212

Total Shareholders Equity

61.5 M 80 M 80 M 67.6 M 65.1 M 60.7 M 68.9 M 70.1 M 86.3 M 80 M 85.3 M 90.8 M 98.3 K 91.8 M 101 M 103 M 110 M 118 M 125 M 132 M 137 M 126 M 25.8 M 33.7 M 33.7 M 25.2 M 23.2 M 27.2 M 20.4 M 20.4 M 27 M 24.2 M 24.2 M 24.2 M 25.9 M 21.9 M 21.9 M 25.9 M 15.2 M 16.8 M 16.8 M 16.8 M -1.59 M -635 K -635 K -635 K -824 K -742 K -742 K -742 K -2.9 M -14.7 K -14.7 K -15 K -1.61 M -45.8 K -45.8 K -47.3 K -1.06 M -23.8 K -23.8 K -26.4 K

All numbers in USD currency

Balance Sheet is a fundamental financial report of Citius Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Repare Therapeutics Repare Therapeutics
RPTX
- - $ 112 M canadaCanada
Sesen Bio Sesen Bio
SESN
- 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
- - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
- -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
- 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
- -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
- -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA